Ophthotech Corporation Eyes $85 Million IPO, Sets Sight on Late-Stage Clinical Trial

Published: Aug 16, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Ophthotech Corporation Files Registration Statement for Proposed Initial Public Offering

NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined.

Morgan Stanley and J.P. Morgan are acting as joint book-running managers for the offering. Leerink Swann and Stifel are acting as co-managers.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; telephone: 866-718-1649; email: prospectus@morganstanley.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204.

About Ophthotech Corporation

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the eye. The company’s most advanced product candidate is Fovista™ anti-PDGF therapy, which it is developing for use in combination with anti-VEGF drugs that represent the standard of care for the treatment of wet age-related macular degeneration.


SmithSolve LLC on behalf of Ophthotech Corporation

Jennifer Devine, 973-442-1555 ext. 102

Help employers find you! Check out all the jobs and post your resume.

Back to news